<DOC>
	<DOC>NCT00560820</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).</brief_summary>
	<brief_title>Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criteria: Male or female patients ≥ 18 years of age without prior history of deferasirox treatment βthalassemia patients receiving regular transfusions every 25 weeks Transfusion history of ≥ 20 units of packed red blood cells Exclusion criteria: Abnormal renal function at baseline ALT greater than 5 x ULN at screening Patients with underlying cardiac disease requiring continuous iron chelation therapy Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>β-thalassemia</keyword>
	<keyword>transfusional iron overload</keyword>
	<keyword>renal function</keyword>
	<keyword>renal biomarkers</keyword>
	<keyword>deferasirox</keyword>
</DOC>